Artigo
Advances in sickle cell disease treatment: From drug discovery until the patient monitoring
Fecha
2011-04-01Registro en:
Cardiovascular and Hematological Agents in Medicinal Chemistry, v. 9, n. 2, p. 113-127, 2011.
1871-5257
1875-6182
10.2174/187152511796196506
2-s2.0-79957964590
9734333607975413
0000-0003-4141-0455
Autor
Universidade Estadual Paulista (Unesp)
Universidade Estadual de Campinas (UNICAMP)
Resumen
Sickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. Nowadays the treatment is performed mainly with drugs such as hydroxyurea or other fetal hemoglobin inducers and chelating agents. This review summarizes current knowledge about the treatment and the advancements in drug design in order to discover more effective and safe drugs. Patient monitoring methods in SCD are also discussed. © 2011 Bentham Science Publishers Ltd.
Materias
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice
Almeida, CB; Scheiermann, C; Jang, JE; Prophete, C; Costa, FF; Conran, N; Frenette, PS -
Advances in sickle cell disease treatment: From drug discovery until the patient monitoring
dos Santos, Jean Leandro; Lanaro, Carolina; Chin, Chung Man -
Advances in sickle cell disease treatment: From drug discovery until the patient monitoring
Universidade Estadual Paulista (Unesp); Universidade Estadual de Campinas (UNICAMP) (2011-04-01)Sickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. ...